Caring We treat everyone with compassion, respect, fairness, and dignity

Size: px

Start display at page:

Download "Caring We treat everyone with compassion, respect, fairness, and dignity"

Bernard Tucker
5 years ago
Views:

2 HEALTH PEI VALUES Caring We treat everyone with compassion, respect, fairness, and dignity Integrity We collaborate in an environment of trust, communicate with openness and honesty, and are accountable through responsible decision-making Excellence We pursue continuous quality improvement through innovation, integration, and the adoption of evidence-based practices

3 WHY DOES URINE MATTER TO YOU? Introduce yourself to your colleagues and share..

4 Objectives: - HOW DID WE GET HERE? - LIAISON PROGRAM - CADTH PRODUCTS - EVIDENCE INFORMED DECISIONS - URINE MATTERS #URINE MATTERS- TWITTER

5 CADTH is a health technology assessment agency We inform technology-related decision-making in health care

6 How did we get here?

7 CADTH S VISION HEALTH TECHNOLOGY ASSESSMENT INFORMS EVERY HEALTH TECHNOLOGY DECISION.

8 CADTH S MISSION TO ENHANCE THE HEALTH OF CANADIANS BY PROMOTING THE OPTIMAL USE OF HEALTH TECHNOLOGIES.

10 KNOWLEDGE SHARING: A CADTH SERVICE

11 Evidence Informed Decision Making.

Commonly Requested Products The following table provides brief descriptions of the products CADTH most commonly produces in response to requests, as well as approximate completion times.

12 Commonly Requested Products The following table provides brief descriptions of the products CADTH most commonly produces in response to requests, as well as approximate completion times. Product Type Description* Approximate turnaround time from point of topic refinement** Reference list Summary of abstracts Summary with critical appraisal Peer-reviewed summary with critical appraisal Systematic review and metaanalysis Rapid health technology assessment Environmental Scan Drug review and formulary recommendation Health technology assessment Optimal use project List of the best available evidence with abstracts and links to full-text documents, if available. Summary based on the abstracts of the best available evidence. Includes the abstracts and links to full-text documents, if available. Written summary of the evidence from full text articles, with a critical appraisal and policy implications. Summary of systematically selected evidence with a critical appraisal and policy implications. An external peer-review is conducted. A systematic review of the evidence and a metaanalysis is performed, where appropriate. Authorship includes a content expert, and an external peer-review is conducted. A systematic review of clinical studies and an economic component that includes a systematic review of economic studies, an economic evaluation or a budget impact analysis. It excludes a review of the health services impact. Authorship includes a content expert, and an external peerreview is conducted. Scan of innovative technologies or pan-canadian access, reimbursement, or practice issues. Rigorous review of the clinical and costeffectiveness of a drug, and a formulary listing recommendation for Canada s publicly funded drug plans (excluding Quebec) through CADTH s Common Drug Review process. Typically, submissions are received from drug manufacturers; however, the CDR-participating drug plans may also request a CDR review. Comprehensive, evidence-based analysis of a health technology or technologies to support and inform decisions about health policy, purchasing, service management, and clinical practice. May include a systematic review of clinical evidence, a systematic review of cost-effectiveness, and information on the broader impact on patient health and the health care system. Project designed to encourage the optimal use of a health technology or technologies by health care providers, policy-makers, and consumers. May include a systematic review of clinical evidence, a systematic review of cost-effectiveness, and development of recommendations, supporting documents, and tools. 5 to 10 business days 15 business days 30 business days Four months 4 to 5 months 5 to 6 months 5 to 40 business days 5 to 6 months Determined on a case-by-case basis Determined on a case-by-case basis *These products may be tailored to meet the needs and timelines of the requestor and are subject to the quality and quantity of the published literature. **The turnaround times are subject to the capacity and ongoing projects at CADTH. Timelines will be negotiated between a CADTH representative and the requestor at the time of topic refinement.

13 RAPID RESPONSE DRUGS DIAGNOSTICS DEVICES SURGICAL AND MEDICAL PROCEDURES

14 Collaboration. PARTNERSHIPS REQUIRED.

15 CADTH ROADSHOW. PANCANADIAN PERSPECTIVES

16 LAB UTILIZATION-A CADTH ROADSHOW

17 SAVE THE DATE! Sharing the results. March 23, 2015 National Webinar

18 Urine Matters. UTI CARE PATHWAYS FOR ENHANCED COLLABORATION & ANTIBIOTIC SAFETY IN SENIORS.

19 Interior Slide Contributing to the conversation about laboratory test optimization and encouraging it to continue.

20 What does the evidence say?

21 Clinical and Cost Effectiveness 1. What is the clinical effectiveness of urine cultures and sensitivity analysis, urine dipstick testing, or urinalysis for urine testing in asymptomatic residents in long term-care? 2. What is the cost effectiveness of urine cultures and sensitivity analysis, urine dipstick testing, or urinalysis for urine testing in asymptomatic residents in long-term care? 20

22 Evidence-based Guidelines 3. What are the evidence-based guidelines regarding the ordering of urine cultures and sensitivity tests, dipstick tests, and urinalysis for residents in longterm care? 4. What are the evidence-based guidelines regarding proper collection of urine for urine testing in longterm care residents? 5. What are the evidence-based guidelines regarding the interpretation of urine test results? 21

23 WHAT DOES THE EVIDENCE SAY? 6. What is the clinical evidence on the development of antibiotic resistance to norfloxaxin in treatment of urinary tract infections (UTIs)? 7. What is the clinical evidence regarding the safety of nitrfurantoin in elderly males with urinary tract infections?

24 What does the evidence say? 8.What is the comparative clinical effectiveness of long-term antibiotic prophylaxis and treatment of urinary tract infections (UTIs) in the elderly? 9.What are the evidence-based guidelines regarding the management of UTIs with antibiotics in the elderly?

Sarah Jennings, BSc, BScPhm, RPh, PharmD Knowledge Mobilization Officer Thursday May 28, 2015 Canadian Pharmacists Conference

Culturing Change in Lab Testing Sarah Jennings, BSc, BScPhm, RPh, PharmD Knowledge Mobilization Officer Thursday May 28, 2015 Canadian Pharmacists Conference CADTH is a health technology assessment (HTA)